Plain language summary: comparing ivonescimab with pembrolizumab in people with PD-L1-positive non-small cell lung cancer in the HARMONi-2 study [0.03%]
HARMONi-2研究：对比伊伏西玛与派姆单抗治疗PD-L1阳性非小细胞肺癌患者的简易总结
Lei Wang,Wenxiu Yao,Hong Shen et al.
Lei Wang et al.
Artificial intelligence in breast cancer: clinical applications in diagnosis, prognosis, and therapeutics [0.03%]
人工智能在乳腺癌的临床应用：诊断、预后和治疗方面
Janhvi Singh,Omar Awad Alsaidan,Alhussain Aodah et al.
Janhvi Singh et al.
Breast cancer (BC) presents a considerable global health challenge and is characterized by increasing mortality and morbidity rates. Prompt screening and accurate diagnosis are crucial for improving patient outcomes. For the assessment of B...
Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation [0.03%]
度伐利尤单抗延长给药间隔、固定剂量（每4周一次）治疗美国不可切除III期NSCLC患者在接受含铂同步放化疗后的疗效和安全性：一项真实世界研究
Reina Haque,Eric McGary,Mike Z Yang et al.
Reina Haque et al.
Background: Durvalumab was initially approved for stage III unresectable non-small cell lung cancer (NSCLC) post-concurrent chemoradiation at 10 mg/kg every two weeks, and starting in November 2020, at 1500 mg every four ...
Clinicopathological significance of common PIK3CA exon mutations in non-metastatic colorectal cancer [0.03%]
非转移性结直肠癌中常见PIK3CA外显子突变的临床病理意义
Jin-Xu Chen,Xiao-Hang Song,Xiao Yang et al.
Jin-Xu Chen et al.
Background: Phosphatidylinositol 3-kinase catalytic subunit Alpha (PIK3CA) is closely correlated with colorectal cancer (CRC). However, the role of PIK3CA in colorectal cancer, particularly in non-metastatic disease, rema...
A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors [0.03%]
AMPECT研究的白话文概述：纳米粒白介素-2抗坏死剂西罗莫司治疗晚期恶性血管周上皮细胞瘤
Andrew J Wagner,Vinod Ravi,Richard F Riedel et al.
Andrew J Wagner et al.
Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors [0.03%]
免疫检查点抑制剂治疗各种类型癌症患者的免疫相关不良事件模式
Matthew J Slaught,Dalia Kaakour,Armon Azizi et al.
Matthew J Slaught et al.
Aims: To investigate the association between primary cancer type and the tissues affected by immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). ...
Real-world cardiac events and outcomes in cBTKi-treated chronic lymphocytic leukemia patients [0.03%]
接受酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者的实际心血管事件及转归
David Dingli,Enrico De Nigris,Siyang Leng et al.
David Dingli et al.
Aim: To evaluate the real-world incidence of cardiovascular adverse events (CVAE) and clinical outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) treated with covalent Bruton...
Correction [0.03%]
改正的方法
Published Erratum
Future oncology (London, England). 2025 Dec 18:1. DOI:10.1080/14796694.2025.2606567 2025
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial [0.03%]
来自ALTA-1L试验的一线brigatinib治疗后的现实世界治疗模式和后续治疗疗效
Myung-Ju Ahn,Angelo Delmonte,Sharmistha Ghosh et al.
Myung-Ju Ahn et al.
Aims: This retrospective, chart-review study evaluated real-world outcomes post-frontline brigatinib in ALTA-1L. Methods: Patients from...
Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer [0.03%]
抗生素辅助的免疫治疗联合粪菌移植应用于食管胃癌患者中可行性分析
Yuri Yoshinami,Shotaro Yamaguchi,Hirokazu Shoji et al.
Yuri Yoshinami et al.
Aims: Immune checkpoint inhibitors (ICIs) have improved outcomes in several malignancies, but survival remains poor for patients with unresectable advanced or recurrent esophageal or gastric cancer. Recent evidence sugges...